The Desmoid Tumor Research Foundation

April 2018

Molecular analyses in the diagnosis and prediction of prognosis in non-GIST soft tissue sarcomas: A systematic review and meta-analysis

Author Information

Kandel RA(1), Yao X(2), Dickson BC(1), Ghert M(3), Popovic S(4), Purgina BM(5), Verma S(6), Werier J(7).

(1)Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. (2)Program in Evidence-Based Care, Cancer Care Ontario; Department of Oncology, McMaster University, Hamilton, Ontario, Canada. (3)Division of Orthopedic Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada. (4)Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. (5)Department of Pathology and Laboratory Medicine, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. (6)Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada. (7)Division of Orthopedic Surgery, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.

Publication

Cancer Treat Rev

Summary

Electronic databases (2005 to October 2016) were searched. Of 6674 identified articles, 70 were eligible and analyzed, covering 13 types of soft tissue sarcomas (STS). Meta-analyses showed that the test of detecting MDM2 amplification by fluorescence in situ hybridization was accurate in differentiating atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcoma from benign tumors or from other STS; that the test of detecting SS18-SSX fusion by reverse transcription polymerase chain reaction (PCR) was accurate in differentiating synovial sarcoma from other STS. The presence of a CTNNB1 S45F mutation detected by PCR was a risk factor for decreased recurrence-free survival in desmoid tumors. The current evidence demonstrates that molecular analyses are useful in the diagnosis and prediction of prognosis in some STS.

View Abstract